- Home
- ACRS vs DDD Comparison
ACRS vs DDD Comparison
Compare ACRS & DDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACRS | DDD |
|---|---|---|
| Founded | 2012 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer peripheral equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.0M | 343.2M |
| IPO Year | 2015 | 2003 |
Fundamental Metrics
Financial Performance| Metric | ACRS | DDD |
|---|---|---|
| Price | $4.54 | $2.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $10.20 | $4.75 |
| AVG Volume (30 Days) | 1.4M | ★ 3.9M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 69.01 | ★ 109.79 |
| EPS | N/A | ★ N/A |
| Revenue | $1,683,000.00 | ★ $386,902,000.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | $4.24 | $4.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.22 | $1.48 |
| 52 Week High | $5.15 | $3.80 |
Technical Indicators
Market Signals| Indicator | ACRS | DDD |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 60.47 |
| Support Level | $4.08 | $1.89 |
| Resistance Level | $5.02 | $3.42 |
| Average True Range (ATR) | 0.26 | 0.22 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 38.04 | 62.32 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About DDD 3D Systems Corporation
3D Systems Corp provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, manufacturing and applications engineering. Its solutions support applications in two key industry verticals: Healthcare Solutions provide surgical planning, implants, instrumentation, and medical education solutions to help medical device manufacturers and healthcare providers accelerate, and ultimately, transform healthcare, and Industrial Solutions which includes aerospace, defense, transportation and general manufacturing. The company operates in the Americas, EMEA, and APAC regions.